ArticleJournal of clinical and experimental hematopathology : JCEH2025
Triple-hit TdT-positive high-grade B-cell lymphoma mimicking B-lymphoblastic lymphoma and exhibiting immunophenotypic change at relapse.
Article in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terminal deoxynucleotidyl transferase (TdT)-positive high-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements ("double/triple-hit" lymphoma) is a rare, aggressive malignancy that often mimics B-lymphoblastic lymphoma (B-LBL), making accurate diagnosis challenging but clinically critical. We report the case of a 63-year-old female with triple-hit HGBCL involving the duodenum, initially presenting with blastoid morphology and a B-LBL-like immunophenotype: TdT(+), CD10(+), CD20(-), BCL6(-), and CD45dim. However, negativity for CD34 and other features inconsistent with B-LBL, such as MUM-1 positivity and cytoplasmic immunoglobulin expression, were also present. Fluorescence in situ hybridization confirmed MYC, BCL2, and BCL6 rearrangements. Despite an initial response to the hyper-CVAD/MA regimen, the patient subsequently relapsed. Relapse biopsies confirmed persistent triple-hit status and clonal identity via IgH gene rearrangement analysis. Unexpectedly, however, the immunophenotype at relapse had changed significantly, with tumor cells becoming TdT(-), CD20(+), and BCL6(+), while remaining CD10(+). Ultimately, the patient died of the disease despite receiving salvage therapies. To our knowledge, this is the first reported case of TdT-positive HGBCL demonstrating loss of TdT expression alongside other immunophenotypic changes at relapse. This case highlights the potential for significant phenotypic change in this rare HGBCL subtype and the importance of comprehensive immunophenotypic and genetic analysis at both diagnosis and relapse for accurate classification and management, particularly in distinguishing it from B-LBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.